Related Experiment Video
Updated: Jan 9, 2026
04:17
Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
Published on: September 27, 2024
1.1K
Deaminase Modulation Driving a New Era in Drug Development
1Department Clinical Pathology, Victorian Comprehensive Cancer Centre (VCCC), Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Melbourne 3052, Australia.
International Journal of Molecular Sciences
|December 11, 2025
Summary
New therapeutics are being developed to treat human diseases by modulating the activity of endogenous mutagenic deaminases, enzymes involved in inflammation pathways. Further research is needed to explore their full therapeutic potential and associated challenges.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Endogenous mutagenic deaminases play complex roles in human diseases.
- These enzymes are intrinsically linked to critical inflammation-related pathways.
- Modulating deaminase activity is a focus for novel therapeutic strategies.
Purpose of the Study:
- To highlight the therapeutic potential of modulating endogenous mutagenic deaminases.
- To explore emerging deaminase-modulating agents and their clinical applications.
- To identify challenges and opportunities in developing deaminase-targeted therapies.
Main Methods:
- Review of current scientific literature on endogenous mutagenic deaminases.
- Analysis of examples illustrating therapeutic modulation of deaminase activity.
- Discussion of challenges and opportunities in the field.
Main Results:
- Deaminase-modulating agents show promise for treating various human diseases.
- Several deaminase-modulating agents are under investigation, with a few already approved.
- The diverse family of deaminases presents significant therapeutic opportunities.
Conclusions:
- Modulating endogenous mutagenic deaminases offers a promising avenue for therapeutic innovation in diseases linked to inflammation.
- Further research is warranted to overcome challenges and fully realize the potential of these targets.
- The development of deaminase-modulating agents represents a significant advancement in drug discovery.
Keywords:
ADAR adenosine deaminasesAID cytosine deaminasesAPOBEC cytosine deaminasescancerchronic diseasesdrug developmentendogenous mutagenic deaminasesfunctional modulation and immunotherapyimmunityinflammationprognosticationsmall molecule deaminase inhibitorsMore Related Videos
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:30Enzyme Inhibition
91.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.2K
01:25Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
01:29Therapeutic Drug Monitoring: Affecting Factors
175
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
175
01:26Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
01:20Desensitization and Tachyphylaxis
2.9K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.9K